Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Health Care Costs | 2 | 2020 | 202 | 0.670 |
Why?
|
| Accountable Care Organizations | 1 | 2021 | 66 | 0.660 |
Why?
|
| Medicare | 2 | 2021 | 601 | 0.630 |
Why?
|
| Patient Readmission | 1 | 2021 | 421 | 0.540 |
Why?
|
| Algorithms | 2 | 2020 | 974 | 0.500 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 789 | 0.400 |
Why?
|
| Medicare Part D | 4 | 2015 | 37 | 0.370 |
Why?
|
| Hospitalization | 6 | 2021 | 1290 | 0.340 |
Why?
|
| Activities of Daily Living | 3 | 2021 | 289 | 0.330 |
Why?
|
| Male | 31 | 2024 | 27747 | 0.310 |
Why?
|
| United States | 16 | 2021 | 7426 | 0.300 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 339 | 0.290 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 5119 | 0.290 |
Why?
|
| Aged | 23 | 2024 | 13406 | 0.290 |
Why?
|
| Patient Compliance | 4 | 2010 | 349 | 0.280 |
Why?
|
| Female | 32 | 2024 | 30724 | 0.270 |
Why?
|
| Early Detection of Cancer | 4 | 2022 | 266 | 0.260 |
Why?
|
| Nursing Homes | 4 | 2021 | 661 | 0.250 |
Why?
|
| Breast Neoplasms | 5 | 2022 | 1118 | 0.250 |
Why?
|
| Physicians, Primary Care | 2 | 2017 | 75 | 0.250 |
Why?
|
| Gout | 4 | 2010 | 48 | 0.240 |
Why?
|
| Humans | 39 | 2024 | 59389 | 0.230 |
Why?
|
| Homes for the Aged | 2 | 2020 | 157 | 0.230 |
Why?
|
| Medication Adherence | 3 | 2011 | 241 | 0.220 |
Why?
|
| Inappropriate Prescribing | 1 | 2024 | 64 | 0.220 |
Why?
|
| Prostate-Specific Antigen | 2 | 2022 | 66 | 0.220 |
Why?
|
| Regression Analysis | 2 | 2020 | 486 | 0.200 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 91 | 0.190 |
Why?
|
| Dementia | 1 | 2024 | 248 | 0.180 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 440 | 0.180 |
Why?
|
| Fractures, Bone | 2 | 2013 | 136 | 0.180 |
Why?
|
| Kallikreins | 1 | 2020 | 8 | 0.170 |
Why?
|
| Diphosphonates | 2 | 2010 | 31 | 0.170 |
Why?
|
| Mobility Limitation | 1 | 2020 | 47 | 0.170 |
Why?
|
| Morbidity | 1 | 2020 | 113 | 0.170 |
Why?
|
| Vaccines | 1 | 2021 | 95 | 0.170 |
Why?
|
| Cystic Fibrosis | 2 | 2011 | 110 | 0.170 |
Why?
|
| Gout Suppressants | 2 | 2010 | 22 | 0.160 |
Why?
|
| Middle Aged | 20 | 2024 | 16314 | 0.160 |
Why?
|
| Forecasting | 1 | 2020 | 221 | 0.160 |
Why?
|
| Retrospective Studies | 7 | 2021 | 6071 | 0.160 |
Why?
|
| Continuity of Patient Care | 2 | 2017 | 170 | 0.150 |
Why?
|
| Cardiovascular System | 1 | 2019 | 38 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2020 | 279 | 0.150 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 2516 | 0.150 |
Why?
|
| Hospitals | 1 | 2021 | 378 | 0.150 |
Why?
|
| Electronic Health Records | 2 | 2020 | 342 | 0.150 |
Why?
|
| Risk Factors | 4 | 2020 | 4986 | 0.140 |
Why?
|
| Physicians | 1 | 2022 | 440 | 0.140 |
Why?
|
| Reminder Systems | 1 | 2017 | 72 | 0.130 |
Why?
|
| Insurance, Health | 2 | 2014 | 144 | 0.130 |
Why?
|
| Antipsychotic Agents | 2 | 2024 | 292 | 0.130 |
Why?
|
| Vaccination | 3 | 2023 | 337 | 0.120 |
Why?
|
| Adult | 12 | 2024 | 15683 | 0.120 |
Why?
|
| Truth Disclosure | 1 | 2015 | 57 | 0.120 |
Why?
|
| Osteoporosis | 3 | 2010 | 102 | 0.120 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2019 | 349 | 0.120 |
Why?
|
| Longitudinal Studies | 5 | 2023 | 1189 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2024 | 3067 | 0.120 |
Why?
|
| Papanicolaou Test | 1 | 2014 | 42 | 0.120 |
Why?
|
| Vaginal Smears | 1 | 2014 | 54 | 0.120 |
Why?
|
| Neoplasm Staging | 2 | 2013 | 448 | 0.110 |
Why?
|
| Health Literacy | 1 | 2014 | 78 | 0.110 |
Why?
|
| Bone Density Conservation Agents | 2 | 2010 | 44 | 0.110 |
Why?
|
| Smoking | 2 | 2009 | 826 | 0.110 |
Why?
|
| Medical Errors | 1 | 2015 | 195 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 135 | 0.110 |
Why?
|
| Heart Failure | 1 | 2020 | 853 | 0.100 |
Why?
|
| Health Status | 1 | 2015 | 426 | 0.100 |
Why?
|
| Databases, Factual | 5 | 2019 | 814 | 0.100 |
Why?
|
| Mammography | 2 | 2022 | 269 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2017 | 648 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2012 | 86 | 0.090 |
Why?
|
| Social Class | 1 | 2012 | 122 | 0.090 |
Why?
|
| Drug Utilization | 2 | 2010 | 208 | 0.090 |
Why?
|
| Tobramycin | 1 | 2011 | 6 | 0.090 |
Why?
|
| Insurance | 1 | 2011 | 18 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 51 | 0.090 |
Why?
|
| Deductibles and Coinsurance | 1 | 2010 | 9 | 0.090 |
Why?
|
| Financing, Personal | 1 | 2010 | 23 | 0.090 |
Why?
|
| Health Services | 1 | 2011 | 81 | 0.090 |
Why?
|
| Survivors | 2 | 2013 | 150 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2011 | 100 | 0.080 |
Why?
|
| Bone Density | 1 | 2010 | 129 | 0.080 |
Why?
|
| Adolescent Behavior | 2 | 2009 | 186 | 0.080 |
Why?
|
| Bone Resorption | 1 | 2010 | 41 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2010 | 94 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 725 | 0.080 |
Why?
|
| Drugs, Generic | 1 | 2009 | 16 | 0.080 |
Why?
|
| Hip Fractures | 1 | 2010 | 63 | 0.080 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 42 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2010 | 156 | 0.080 |
Why?
|
| Massachusetts | 3 | 2024 | 2019 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 168 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2013 | 674 | 0.080 |
Why?
|
| Confidence Intervals | 4 | 2010 | 241 | 0.080 |
Why?
|
| Age Factors | 4 | 2020 | 1504 | 0.080 |
Why?
|
| Poverty | 1 | 2010 | 283 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2008 | 52 | 0.070 |
Why?
|
| Family | 1 | 2009 | 229 | 0.070 |
Why?
|
| Students | 1 | 2009 | 202 | 0.070 |
Why?
|
| Health Maintenance Organizations | 1 | 2007 | 59 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 117 | 0.070 |
Why?
|
| Insurance Claim Review | 1 | 2007 | 76 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 515 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 2338 | 0.070 |
Why?
|
| Pandemics | 2 | 2022 | 617 | 0.070 |
Why?
|
| Cohort Studies | 5 | 2011 | 2375 | 0.070 |
Why?
|
| Young Adult | 4 | 2024 | 4272 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2014 | 527 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 284 | 0.060 |
Why?
|
| Time Factors | 4 | 2017 | 3615 | 0.060 |
Why?
|
| Adolescent | 6 | 2011 | 5838 | 0.060 |
Why?
|
| Computer Communication Networks | 1 | 2005 | 13 | 0.060 |
Why?
|
| Cholinergic Antagonists | 1 | 2024 | 33 | 0.060 |
Why?
|
| Deprescriptions | 1 | 2024 | 24 | 0.060 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 62 | 0.060 |
Why?
|
| Registries | 2 | 2005 | 799 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2005 | 57 | 0.060 |
Why?
|
| Medical Informatics | 1 | 2005 | 67 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 248 | 0.060 |
Why?
|
| Child | 5 | 2011 | 4189 | 0.060 |
Why?
|
| Trust | 1 | 2024 | 67 | 0.050 |
Why?
|
| Health Services Research | 1 | 2005 | 266 | 0.050 |
Why?
|
| Risk Assessment | 4 | 2011 | 1925 | 0.050 |
Why?
|
| Patient Participation | 1 | 2024 | 216 | 0.050 |
Why?
|
| Intention | 1 | 2022 | 64 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2005 | 256 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 2380 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 453 | 0.050 |
Why?
|
| Mass Screening | 2 | 2022 | 648 | 0.040 |
Why?
|
| Michigan | 1 | 2020 | 41 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2020 | 61 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2020 | 72 | 0.040 |
Why?
|
| Allopurinol | 2 | 2010 | 15 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 108 | 0.040 |
Why?
|
| Uric Acid | 2 | 2010 | 45 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 176 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 55 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 131 | 0.040 |
Why?
|
| Incidence | 2 | 2013 | 1238 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2020 | 292 | 0.040 |
Why?
|
| Peer Group | 2 | 2009 | 95 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 679 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2010 | 746 | 0.040 |
Why?
|
| Perception | 2 | 2009 | 168 | 0.040 |
Why?
|
| Data Collection | 1 | 2019 | 371 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1051 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2010 | 902 | 0.040 |
Why?
|
| Survival Rate | 2 | 2013 | 801 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2011 | 1793 | 0.030 |
Why?
|
| Tobacco Use Disorder | 2 | 2009 | 243 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 42 | 0.030 |
Why?
|
| Prognosis | 2 | 2013 | 1597 | 0.030 |
Why?
|
| Neoplasms | 1 | 2005 | 1231 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 119 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2015 | 112 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 1027 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 492 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 228 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 399 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 551 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 300 | 0.020 |
Why?
|
| Deoxyribonuclease I | 1 | 2011 | 40 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2010 | 74 | 0.020 |
Why?
|
| Legislation, Drug | 1 | 2010 | 17 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 454 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 2010 | 31 | 0.020 |
Why?
|
| Colchicine | 1 | 2010 | 27 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 326 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 167 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2010 | 99 | 0.020 |
Why?
|
| Sulfinpyrazone | 1 | 2009 | 2 | 0.020 |
Why?
|
| Probenecid | 1 | 2009 | 5 | 0.020 |
Why?
|
| Income | 1 | 2010 | 157 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 409 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2010 | 116 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2010 | 124 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 355 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 396 | 0.020 |
Why?
|
| Tobacco Industry | 1 | 2008 | 19 | 0.020 |
Why?
|
| Child Behavior | 1 | 2009 | 63 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2010 | 180 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 202 | 0.020 |
Why?
|
| Age of Onset | 1 | 2008 | 170 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2008 | 57 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 805 | 0.020 |
Why?
|
| Commerce | 1 | 2008 | 53 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2008 | 39 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 742 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2008 | 68 | 0.020 |
Why?
|
| Tobacco Products | 1 | 2008 | 71 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1022 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 52 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 935 | 0.020 |
Why?
|
| Epilepsy | 1 | 2008 | 105 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 717 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2007 | 94 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2006 | 91 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 1234 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 735 | 0.010 |
Why?
|
| SEER Program | 1 | 2005 | 66 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 1479 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 1078 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 108 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 124 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 111 | 0.010 |
Why?
|
| Hypertension | 1 | 2008 | 570 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 635 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2010 | 5281 | 0.010 |
Why?
|